Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B

Journal of Infectious Diseases

Volumn 183, Issue 2, 2001, Pages 253-260

  Saeland, Eirikur ^a,b   Jakobsen, Håvard ^a   Ingolfsdottir, Gunnhildur ^a   Sigurdardottir, Sigurveig T ^a   Jonsdottir, Ingileif ^a  

^a Landspitali University Hospital   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; OPSONIN; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTEREMIA; CONTROLLED STUDY; CROSS REACTION; DISEASE CONTROL; FEMALE; HUMAN; INFANT; INFECTION CONTROL; LUNG INFECTION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; BACTEREMIA; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; LUNG DISEASES; MICE; OPSONIN PROTEINS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 0035863550     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/317934     Document Type: Article

References (50)

1. Pneumococcal bacteremia with special reference to bacteraemic pneumococcal pneumonia
2. Considerations for formulating the second generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups
3. Preventing pneumococcal disease in children: Recommendations for using pneumococcal vaccine
4. The bacteriology of pneumococcal otitis media
5. The epidemiology of pneumococcal disease in infants and children
6. Epidemiology of invasive pneumococcal infections in children in Finland
7. Epidemiology of invasive childhood pneumococcal infections in Israel
8. Pneumococcal bacteremia in Monroe County, New York
9. Serotypes responsible for invasive Streptococcus pneumoniae infections among children in Connecticut
10. Antimicrobial resistance in Streptococcus pneumoniae: An overview
11. Drug resistant Streptococcus pneumoniae
12. Natural and vaccine-related immunity to Streptococcus pneumoniae
13. Pneumococcal disease: Prospects for a new generation of vaccines
14. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants
15. Pneumococcal vaccine and otitis media
16. Antibody response to pneumococcal vaccination in children younger than five years of age
17. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children
18. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations
19. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens
20. Functional activity of antibodies elicited by octavalent pneumococcal polysaccharide conjugate vaccines, PncT and PncD
21. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants
22. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants
23. Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid
24. Molecular analysis of the pathogenicity of Streptococcus pneumoniae: The role of pneumococcal proteins
25. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
26. Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model
27. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae
28. The repertoire of human antibodies to the carbohydrate capsule of Streptococcus pneumoniae 6B
29. IgG subclass response and opsonization of Streptococcus pneumoniae after vaccination of healthy adults
30. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae
31. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine
32. Assignment of immunoglobulin G1 and G2 concentrations to pneumococcal capsular polysaccharides 3, 6B, 14, 19F, and 23F in pneumococcal reference serum 89-SF
33. The role of pH in modified ELISA procedures used for the estimation of functional antibody affinity
34. Comparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides
35. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants
36. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections
37. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic LT-mutants from Escherichia coli as adjuvants protects mice against invasive pneumococcal infections
38. Assessment of the antibody response to pneumococcal vaccine in high-risk populations
39. Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats
40. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae
41. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic
42. Removal of additional cross-reactive antibodies improves the functional specificity in sera from adults immunized with pneumococcal polysaccharides
43. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides
44. Avidity, functional potency, and cross-reactivity of monoclonal antibodies to pneumococcal capsular polysaccharide serotype 6B
45. Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcαRI (CD89)